RecruitingPhase 2Phase 3NCT04297683
HEALEY ALS Platform Trial - Master Protocol
HEALEY ALS Platform Trial
Sponsor
Merit E. Cudkowicz, MD
Enrollment
1,500 participants
Start Date
Jun 14, 2020
Study Type
INTERVENTIONAL
Conditions
Summary
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Eligibility
Min Age: 18 Years
Inclusion Criteria9
- Sporadic or familial ALS diagnosed as clinically possible, probable, lab-supported probable, or definite ALS defined by revised El Escorial criteria.
- Age 18 years or older.
- Capable of providing informed consent and complying with study procedures, in the SI's opinion.
- Time since onset of weakness due to ALS ≤ 24 months at the time of the Master Protocol Screening Visit.
- Vital Capacity ≥ 50% of predicted capacity at the time of the Master Protocol Screening Visit measured by Slow Vital Capacity (SVC), or, if required due to pandemic-related restrictions, Forced Vital Capacity (FVC) measured in person.
- Participants must either not take riluzole or be on a stable dose of riluzole for ≥ 30 days prior to the Master Protocol Screening Visit.
- Participants must either not take edaravone or have completed at least one cycle (typically 14 days) of edaravone prior to the Master Protocol Screening Visit.
- Participants must have the ability to swallow pills and liquids at the time of the Master Protocol Screening Visit and, in the SI's opinion, have the ability to swallow for the duration of the study.
- Geographically accessible to the site.
Exclusion Criteria9
- Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant, according to SI's judgment (e.g., cardiovascular instability, systemic infection), or clinically significant laboratory abnormality or EKG changes. Clinically significant abnormal liver or kidney function is exclusionary. The following values \[alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3 times the upper limit of normal (ULN) or estimated Glomerular Filtration Rate (eGFR) \< 30 mL/min/1.73m2\] are exclusionary regardless of clinical symptoms.
- Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed consent, in the SI's opinion.
- Active cancer or history of cancer, except for the following: basal cell carcinoma or successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies curatively treated and with no evidence of disease recurrence for at least 3 years.
- Use of investigational treatments for ALS (off-label use or active participation in a clinical trial) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the Master Protocol Screening Visit.
- Exposure at any time to any gene therapies under investigation for the treatment of ALS (off-label use or investigational).
- If female, breastfeeding, known to be pregnant, planning to become pregnant during the study, or of child-bearing potential and unwilling to use effective contraception, for the duration of the trial and for 3 months, or as specified in each RSA, after discontinuing study treatment.
- If male of reproductive capacity, unwilling to use effective contraception for the duration of the trial and for 3 months, or as specified in each RSA, after discontinuing study treatment.
- Anything that would place the participant at increased risk or preclude the participant's full compliance with or completion of the study, in the SI's opinion.
- If a participant is being re-screened, the disqualifying condition has not been resolved, or the mandatory wash-out duration has not occurred.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGZilucoplan
Drug: Zilucoplan Administration: Subcutaneous injection Dose: Minimum of .0.22 mg/kg daily to a maximum dose of 0.42 mg/kg daily, dependent on weight
DRUGVerdiperstat
Drug: Verdiperstat Administration: Oral Dose: 600mg twice daily
DRUGCNM-Au8
Drug: CNM-Au8 Administration: Oral Dose: 30 mg or 60 mg daily
DRUGPridopidine
Drug: Pridopidine Administration: Oral Dose: 45mg twice daily
DRUGSLS-005 Trehalose
Drug: SLS-005 Trehalose Administration: Infusion Dose: 0.75 g/kg weekly
DRUGABBV-CLS-7262
Drug: ABBV-CLS-7162 Administration: Oral Dose: Dose 1 or Dose 2
DRUGDNL343
Drug: DNL343 Administration: Oral Dose: Once per day
DRUGNUZ-001
Drug: NUZ-001. Administration: Oral. Dose: Once per day.
Locations(74)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04297683
Related Trials
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
NCT032251441 location
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
NCT0540732435 locations
Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Sclerosis
NCT075026771 location
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT072900623 locations
The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study
NCT003176161 location